an 168

BL-1020 Mesylate (CYP-1020 Mesylate) is an orally available GABA A receptor agonist and D2 antagonist that decreases dopamine activity and enhances GABAA activity.BL-1020 Mesylate has been used in the study of schizophrenia, Alzheimer's disease, and bi-directional cognitive impairment.

EGFR-IN-168 (Compound 9a) is a potent EGFR inhibitor with an IC50 of 0.069 μM and demonstrates antitumor activity.

Antioxidant 168 (Tris(2,4-di-tert-butylphenyl) phosphite) is a high-performance solid organophosphite secondary antioxidant. As an essential additive in the processing of polymer materials, Antioxidant 168 is widely used for stabilization treatment during the processing of polyolefins, polycarbonates, ABS, and other materials, owing to its low volatility, excellent thermal stability, and outstanding hydrolysis resistance. The core mechanism of action of Antioxidant 168 lies in its ability to efficiently decompose hydroperoxides generated by thermal oxidation during material processing, thereby inhibiting the degradation chain reaction of polymers.

ST-168 is a potent inhibitor of PI3K and MEK. ST-168 displays improved PI3K and MEK1 isoform inhibition. ST-168 demonstrated a 2.8-, 2.7-, 23-, and 2.5-fold improved inhibition toward the PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ isoforms and a 2.2-fold improvement

Compound D16 (Anticancer agent 168) is an inhibitor of DNA2 that induces apoptosis and cell-cycle arrest predominantly in the S-phase. It demonstrates anticancer efficacy and can counteract chemotherapy resistance in cancers harboring mutant p53 [1].

Antitumor agent-168 (compound 21b) disrupts the microtubule networks within tumor cells, leading to G2/M cell cycle arrest and induction of apoptosis. It inhibits the growth of MCF-7 cells with an IC50 value of 1.4 nM.

BF-168 is a candidate probe for PET and specifically recognizes both neuritic and diffuse plaques (Ki: 6.4 nM for Aβ1-42).

JC168 is a phenyl analog of peloruside and functions as a microtubule inhibitor with antiproliferative and anticancer properties. It enhances tubulin polymerization, thereby disrupting microtubule dynamics, making it a useful agent in the study of microtubule-associated diseases.

E3 Ligase Ligand-linker Conjugate 168 is a compound composed of a ligand for the E3 ligase Cereblon and a linker. It is utilized in the synthesis of PROTAC c-Met degrader-3.

LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.

NEP168 is an ERα PROTAC degrader designed based on the GID4 E3 ligase. It is intended for breast cancer research.

GNKG168 is an unmethylated CpG oligonucleotide. It functions as an immune stimulant by acting as a TLR9 agonist.

GNKG168 sodium is an unmethylated CpG oligonucleotide that acts as an immune stimulant by serving as a TLR9 agonist.

CB 168 is a potent selective aminoacylaminoaryl tetrazole inhibitor targeting isoleucine tRNA synthetase (IleRS).

Tat-peptide 168-189, a cell-permeable, Tat-labeled fusion peptide derived from residues 168-189 of rat G3BP1, features the HIV Tat sequence at its least conserved terminus to enhance cellular uptake. It serves as the negative control for Tat-peptide 168-189 TFA, which promotes axon growth and neurite proliferation [1].

ETC-168 is a selective, orally active MNK inhibitor with IC50 values of 23 nM for MNK1 and 43 nM for MNK2. It demonstrates antiproliferative efficacy both in vivo and in vitro [1].

Tris(2,4-di-tert-butylphenyl)phosphite (Standard) is a reference standard of Tris(2,4-di-tert-butylphenyl)phosphite intended for quantitative analysis, quality control, and related biochemical research applications.

Tat-peptide 168-189 is a cell-permeable Tat-tagged fusion peptide corresponding to residues 168-189 of rat G3BP1. The Tat sequence from HIV is incorporated at the least conserved end of this sequence to enhance cellular permeability. Serving as a negative control for Tat-peptide 190-208, Tat-peptide 168-189 contrasts with Tat-peptide 190-208, which promotes axon growth and increases the number of neurites per neuron.

RCP168 is a highly selective and potent CXCR4 receptor antagonist with an IC50 of 5 nM. It exhibits superior capacity to inhibit HIV-1 (Human Immunodeficiency Virus type 1) from entering host cells via the CXCR4 receptor compared to natural chemokines. RCP168 suppresses HIV-1 infection by blocking viral binding sites or inducing receptor internalization. It can be utilized in research to study interactions between the CXCR4 receptor and other chemokine receptors.

endo-α-1,5-Arabinanase, Bacillus subtilis 168 (EC.3.2.1.99), is a glycoside hydrolase involved in the degradation of arabinans. The enzyme exo-α-1,5-Arabinanase is capable of cleaving the main chain of arabinans.

Exo-α-Arabinofuranosidase, Bacillus subtilis 168 (EC.3.2.1.55), is a glycoside hydrolase enzyme.

(R)-ADX-47273 is a potent positive allosteric modulator of mGluR5, with an EC50 of 168 nM for potentiation.

CAIX/XII/NAMPT-IN-1 is a triple inhibitor targeting carbonic anhydrase IX/XII (CAIX/XII) and nicotinamide phosphoribosyltransferase (NAMPT), with a Ki of 78.1 nM for hCA IX, a Ki of 64.4 nM for hCA XII, and an IC50 of 168 nM for hNAMPT. It induces apoptosis, promotes the accumulation of reactive oxygen species (ROS), inhibits the ERK/AKT signaling pathway, blocks DNA synthesis, and disrupts mitochondrial function. CAIX/XII/NAMPT-IN-1 exhibits antiproliferative effects on various cancer cells under both normoxic and hypoxic conditions. This compound is useful for cancer research, including studies on renal cancer, glioblastoma, and colorectal cancer.

PMX-205 is a cyclic hexapeptide that acts as a potent antagonist of C5a receptor (C5aR; IC50= 31 nM).1It is orally active and blocks inflammatory signaling and symptoms in animal models of colitis and allergic asthma.2,3PMX-205 is also brain penetrant and reduces neuroinflammation and neurodegeneration in an animal model of Alzheimer's disease.4 1.March, D.R., Proctor, L.M., Stoermer, M.J., et al.Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activityMol. Pharmacol.65(4)868-879(2004) 2.Jain, U., Woodruff, T.M., and Stadnyk, A.W.The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10Br. J. Pharmacol.168(2)488-501(2013) 3.Staab, E.B., Sanderson, S.D., Wells, S.M., et al.Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaInt. Immunopharmacol.21(2)293-300(2014) 4.Fonseca, M.I., Ager, R.R., Chu, S.-H., et al.Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's diseaseJ. Immunol.183(2)1375-1383(2009)